V. S. Guillen

Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.

B. Katzenellenbogen, J. Katzenellenbogen, K. Nettles, 2017, Cancer research.

Effect of PD-1: PD-L1 in Invariant Natural Killer T-Cell Emigration and Chemotaxis Following Sepsis

D. Heffernan, W. Cioffi, C. Chung, 2016, Shock.

Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells.

B. Katzenellenbogen, S. Srinivasan, J. Katzenellenbogen, 2017, Journal of medicinal chemistry.

Transcription Regulation and Genome Rewiring Governing Sensitivity and Resistance to FOXM1 Inhibition in Breast Cancer

B. Katzenellenbogen, J. Katzenellenbogen, Sung Hoon Kim, 2021, Cancers.

Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs

B. Katzenellenbogen, J. Katzenellenbogen, Sung Hoon Kim, 2023, Breast Cancer Research and Treatment.

New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons.

Jian Min, Abhishek Sharma, Sarat Chandarlapaty, 2018, ACS medicinal chemistry letters.

Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain.

B. Katzenellenbogen, S. Chandarlapaty, J. Katzenellenbogen, 2018, ACS chemical biology.

Dual-mechanism estrogen receptor inhibitors expand the repertoire of anti-hormone therapy for breast cancer

B. Katzenellenbogen, J. Nwachukwu, S. Srinivasan, 2020, bioRxiv.

Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer

B. Katzenellenbogen, J. Katzenellenbogen, V. S. Guillen, 2023, Breast Cancer Research.